FOXO4-DRI Dosage Guide

Preclinical senolytic peptide protocols, mouse-to-human dose scaling, cycling strategies, and safety considerations from 16 published studies and community experience.

Compiled by PeptideWiki Editorial Team

What Is FOXO4-DRI?

FOXO4-DRI is a 43-amino-acid synthetic senolytic peptide designed to selectively eliminate senescent cells (aged, damaged cells that have stopped dividing but resist normal programmed death). FOXO4-DRI was first described by Peter de Keizer and colleagues in a landmark 2017 paper published in Cell (PMID: 28340339).

The “DRI” stands for D-retro-inverso, a peptide engineering strategy where all amino acids are replaced with their mirror-image forms (D-amino acids) and the sequence is reversed. This modification makes the peptide highly resistant to enzyme breakdown while preserving its ability to bind its biological target. In practice, this means FOXO4-DRI survives much longer in the body than a standard peptide would.

FOXO4-DRI works by disrupting the interaction between two proteins inside senescent cells: FOXO4 and p53. In senescent cells, FOXO4 keeps p53 locked in the nucleus, preventing the cell from triggering its own death. FOXO4-DRI competes with FOXO4 for that binding site, releasing p53 to activate natural programmed cell death (apoptosis). Because FOXO4 is only upregulated in senescent cells, healthy cells are largely unaffected.

Use our Peptide Dosage Calculator to calculate your exact dose based on vial size and concentration.

FOXO4-DRI has never been tested in humans in any clinical setting. All published data comes from cell culture and mouse studies. Dosing information in this guide is derived from animal research and community self-experimentation, not from human clinical trials.

Key Characteristics:

Senolytic peptide — selectively triggers programmed cell death in senescent cells while sparing healthy cells (demonstrated in mouse studies)
D-retro-inverso design — mirror-image amino acids that resist enzyme breakdown, giving the peptide significantly longer biological activity than standard peptides
FOXO4-p53 disruption — releases p53 from its sequestered state in senescent cells, allowing it to trigger natural cell death via the mitochondrial apoptosis pathway
Preclinical evidence only — 16 published papers across 9 tissues and conditions, all in cell culture or animal models. Zero human clinical trials registered as of April 2026
Short pulsed cycling — used in brief intensive courses (3–20 days) repeated 1–3 times per year, not as a continuous daily peptide
Subcutaneous injection — the standard community route; published mouse studies used intravenous or intraperitoneal injection

New to peptides? Start with the Beginner's Guide to Peptides.

How FOXO4-DRI Dosage Is Determined

FOXO4-DRI dosing is uniquely challenging because there is no human pharmacokinetic data, no clinical trial data, and the gap between the mouse study dose and what community users actually take is enormous. Understanding where the numbers come from is essential context for anyone evaluating protocols.

The Landmark Mouse Study (Baar et al. 2017)

The only published in vivo dosing protocol comes from the original 2017 Cell paper. Mice received 5 mg/kg body weight by intravenous injection, given as 3 doses on alternating days (days 1, 3, and 5). Total exposure was 15 mg/kg over 5 days. For a 25-gram mouse, each injection was approximately 0.125 mg. Subsequent mouse studies (Zhang 2020, Han 2022, Liu 2023) used the same 5 mg/kg dose and reported similar tolerability.

Allometric Scaling to Human Doses

The FDA standard body surface area (BSA) conversion uses Km factor ratios to translate animal doses to human equivalent doses (HED). For mouse to human:

Human Equivalent Dose Calculation:

HED (mg/kg) = Mouse dose (mg/kg) × (Km_mouse ÷ Km_human)
HED = 5 mg/kg × (3 ÷ 37) = 0.41 mg/kg
For a 70 kg person: 0.41 × 70 = ~28.5 mg per dose
Full protocol (3 doses): ~85.5 mg total

These are rough estimates only. The mouse study used IV administration; subcutaneous bioavailability in humans is unknown. No human pharmacokinetic data exists to validate this conversion.

Community & Practitioner Experience

Across a small number of documented community protocols, the actual doses used are 5–20 times below the calculated HED. Most self-experimenters use 1–3 mg per dose subcutaneously, given every other day for 10–20 days. More experienced users have progressed to 3–8 mg per dose over multiple protocol revisions, keeping total cycle exposure under approximately 25 mg.

The gap between HED and community doses reflects cost ($200+ per 10 mg vial), injection site pain at higher volumes, and appropriate caution with a compound that has no human safety data.

Strength of evidence: Low (preclinical only). All dosing data comes from mouse studies and uncontrolled self-experimentation. No human pharmacokinetic, dose-finding, or safety studies have been published. The allometric scaling provides a mathematical starting point, not a validated therapeutic dose.

Standard FOXO4-DRI Dosage Ranges

Because no clinical dose has been established, the following ranges represent the spectrum of what has been used in published animal research and community self-experimentation. Two distinct dosing philosophies exist: the research-derived approach based on allometric scaling from mouse data, and the community approach based on collective experience at much lower doses.

Community Protocol (Subcutaneous Injection)

Level	Dose	Frequency	Notes
Low / Starter	1–2 mg	Every other day	Most commonly reported starting dose; assess tolerance before increasing
Standard	2–3 mg	Every other day	Middle of the community range; total cycle dose typically 10–24 mg
Experienced / Aggressive	6–8 mg	Daily for 3–4 days	Used by long-term practitioners; total ~24 mg per cycle; approaches lower end of HED range

Research-Derived Protocol (Allometric Scaling)

Body Weight	Single HED Dose	Full Protocol (3 Doses)	Notes
60 kg (132 lb)	~24 mg	~73 mg	3 doses q48h (days 1, 3, 5)
70 kg (154 lb)	~28.5 mg	~85.5 mg	3 doses q48h (days 1, 3, 5)
80 kg (176 lb)	~32.5 mg	~97.5 mg	3 doses q48h (days 1, 3, 5)
90 kg (198 lb)	~36.5 mg	~110 mg	3 doses q48h (days 1, 3, 5)

Be honest about the gap. Community doses (1–8 mg) are 5–20 times below the allometrically scaled HED (~28 mg for 70 kg). Whether sub-HED doses produce meaningful senolytic activity in humans is completely unknown. Some users report subjective improvements at low doses, but placebo effects cannot be excluded without controlled studies.

Calculate Your FOXO4-DRI Dose

FOXO4-DRI is supplied as a lyophilized (freeze-dried) powder, typically in 10 mg vials. You reconstitute it with bacteriostatic water, then draw your dose using an insulin syringe.

Worked Example:

Vial size: 10 mg (10,000 mcg) of FOXO4-DRI
Bacteriostatic water added: 1 mL
Concentration: 10,000 mcg ÷ 1 mL = 10,000 mcg per mL (10 mg/mL)
Target dose: 2 mg (2,000 mcg)
Volume to draw: 2,000 ÷ 10,000 = 0.2 mL = 20 units on an insulin syringe

Quick Reference — 10 mg Vial

Bac Water Added	Concentration	2 mg Dose	Doses per Vial
0.5 mL	20 mg/mL	10 units (0.1 mL)	5 doses
1 mL	10 mg/mL	20 units (0.2 mL)	5 doses
2 mL	5 mg/mL	40 units (0.4 mL)	5 doses

Skip the Math — Use Our

Enter your vial size, water volume, and desired dose — get instant calculations with zero manual math.

How to Reconstitute FOXO4-DRI

FOXO4-DRI comes as a lyophilized (freeze-dried) powder that must be reconstituted with bacteriostatic water before injection. This process is straightforward but requires clean technique to maintain sterility and peptide integrity.

Supplies Needed:

FOXO4-DRI lyophilized vial (10 mg)
Bacteriostatic water (BAC water) — contains 0.9% benzyl alcohol as preservative
Insulin syringes (29–31 gauge, 0.5 mL or 1 mL) for injection
Alcohol swabs (70% isopropyl alcohol)
Clean, flat workspace

Steps

Wash Hands & Prepare Workspace

Wash hands thoroughly with soap and water. Lay out supplies on a clean surface: FOXO4-DRI vial, bacteriostatic water, insulin syringe, and alcohol swabs.

Remove the Vial Caps

Flip off the plastic caps from both the FOXO4-DRI vial and the bacteriostatic water vial. Swab both rubber stoppers with alcohol pads and let them air-dry for 10–15 seconds.

Draw Bacteriostatic Water

Using a fresh insulin syringe, draw 1 mL of bacteriostatic water. For a 10 mg vial, 1 mL gives a concentration of 10 mg/mL (10,000 mcg/mL), making dose calculations straightforward.

Add Water to the Peptide Vial

Insert the needle into the FOXO4-DRI vial through the rubber stopper. Angle the needle so the water runs down the inside glass wall — never squirt directly onto the powder cake. Release the plunger slowly.

Dissolve Gently

Remove the syringe. Let the vial sit for 1–2 minutes, then gently swirl or roll between your palms until the powder is fully dissolved. The solution should be clear and colorless. Never shake.

Label & Refrigerate

Write the reconstitution date and concentration on the vial. Store refrigerated at 2–8°C. Use within 28–30 days. Protect from light by keeping the vial in its box or wrapped in foil.

Storage

Unreconstituted (powder): Store refrigerated (2–8°C) or frozen (–20°C) for maximum shelf life
Reconstituted (in bacteriostatic water): Must be refrigerated at 2–8°C; use within 28–30 days
Do not freeze: Freezing reconstituted peptide can damage the structure through ice crystal formation
Protect from light and heat — keep the vial in its box or wrapped in foil, away from direct sunlight

For a detailed visual walkthrough, see our How to Reconstitute Peptides guide.

FOXO4-DRI Dosage by Goal

Unlike peptides where dose and duration change significantly based on the target, FOXO4-DRI's core mechanism (senescent cell clearance) applies across all goals. The protocol itself varies less than the monitoring approach and complementary compounds. All applications below are based on preclinical research and community protocols, not clinical evidence.

Goal	Dose	Frequency	Duration	Notes
General anti-aging	2–3 mg	EOD	10–20 days	Standard protocol; Baar 2017 showed restored fur density, kidney function, and fitness in aged mice
Testosterone support	2–3 mg	EOD	5–10 days	Zhang 2020 showed testosterone improvement in aged mice 30 days post-treatment; clearance of senescent Leydig cells
Joint and cartilage health	1–2 mg	EOD	10–14 days	Huang 2021 showed clearance of senescent chondrocytes in vitro; community reports of reduced joint pain
Skin and tissue quality	1–3 mg	EOD	10–20 days	Community reports of improved skin firmness and texture; consider following with a GHK-Cu course for tissue rebuilding
Vascular health	2–3 mg	EOD	5–10 days	Hu 2026 showed improved aortic function in aged mice; use caution and consult a physician if you have cardiovascular conditions

All applications are experimental. None of these use cases have been validated in human clinical trials. The research citations refer to animal or in vitro studies only. Consult a healthcare provider before using FOXO4-DRI for any purpose.

FOXO4-DRI Injection Guide

FOXO4-DRI is administered by subcutaneous (SubQ) injection. Injection site soreness is one of the most commonly reported side effects, often lasting several days, so proper technique and site rotation are particularly important for this peptide.

Recommended Injection Sites

Abdominal fat (preferred): Pinch a fold of skin 1–2 inches from the navel. Inject at a 45-degree angle using a 29–31 gauge insulin syringe.
Upper thigh: Front of the thigh, outer area. Alternate with abdominal sites to reduce soreness accumulation.
Upper arm: Back of the upper arm. May require assistance. Less fatty tissue can increase discomfort.

Site Rotation Strategy

Some community users deliberately rotate injection sites across different body areas during each cycle. The rationale is that subcutaneous injection delivers the peptide primarily to local tissues first, so spreading injections across the abdomen, thighs, and arms may distribute the senolytic effect more broadly. Whether this actually improves outcomes is unproven, but it does reduce localized injection site soreness.

Technique Tips

Use insulin syringes: 29–31 gauge, 0.5 mL or 1 mL capacity
Inject slowly: Rapid injection can increase local tissue irritation and soreness
Room temperature peptide: Remove the vial from the refrigerator 5–10 minutes before injection to reduce discomfort from cold solution
No aspiration needed: For subcutaneous injection with insulin syringes, aspiration (pulling back the plunger to check for blood) is not necessary
Rotate sites by at least 1 inch from the previous injection point to minimize irritation

Injection site soreness is notably more common with FOXO4-DRI than with most other peptides. Some community users report soreness lasting several days at higher doses. Start with 1–2 mg to assess your individual response before increasing dose volume.

FOXO4-DRI Cycle Duration

FOXO4-DRI is a senolytic, not a daily maintenance peptide. It is designed to be used in short, intensive courses that trigger senescent cell clearance, followed by extended rest periods that allow the body to recover and regenerate. This cycling approach mirrors the original mouse study protocol and the broader senolytic therapy model.

Common Cycling Protocols

Protocol	Cycle Length	Cycles per Year	Source
Mouse study model	3 doses over 5 days (q48h)	Single course studied	Baar et al. 2017
Short pulse	3–5 days	2–3x per year	Community protocols
Standard course	10–14 days (EOD dosing)	2x per year	Community protocols
Extended course	20–30 days (EOD dosing)	1–2x per year	Community protocols

Rest Period Between Cycles

A minimum of 4–6 months between FOXO4-DRI cycles is the community consensus. A PCC1 researcher has recommended senolytic clearing only once every 6–8 months. The biological rationale is that senescent cell clearance triggers tissue remodeling and regeneration that takes weeks to months to complete. Running cycles too frequently may interfere with this recovery process and provides diminishing returns as the senescent cell pool shrinks.

When to Stop a Cycle Early

Severe or persistent flu-like symptoms lasting more than 48 hours
Significant blood pressure changes (monitor if you have cardiovascular risk factors)
Unusual neurological symptoms (numbness, tingling that does not resolve)
Signs of infection or illness unrelated to the peptide
Any symptom that concerns you enough to question continuing

Diminishing returns within a cycle. Based on the senolytic mechanism, the first several doses likely do the majority of senescent cell clearance as they target the most vulnerable cells. Later doses encounter a progressively smaller pool of remaining senescent cells. This is why community protocols tend toward shorter, higher-dose pulses rather than prolonged low-dose courses.

FOXO4-DRI Stacking Protocols

FOXO4-DRI is typically sequenced with other compounds rather than stacked simultaneously. The core principle is: clear senescent cells first, then rebuild. Running growth-promoting or regenerative peptides during active senolytic treatment sends conflicting biological signals. The following protocols reflect the community approach to phased longevity stacking.

FOXO4-DRI + Epitalon — Senolytic-Longevity Sequence

Clear senescent cells first with FOXO4-DRI, then follow with an Epitalon cycle (10 mg/day for 10 days) to activate telomerase and support cellular renewal. Epitalon addresses telomere maintenance, a separate hallmark of aging, complementing FOXO4-DRI's senescent cell clearance. Wait 1–2 weeks after completing the FOXO4-DRI course before starting Epitalon.

Week 1–2: FOXO4-DRI 2–3 mg EOD (senolytic phase)
Week 3: Rest (clearance and recovery)
Week 4–5: Epitalon 10 mg/day (telomerase activation)

FOXO4-DRI + GHK-Cu — Clear and Rebuild

After FOXO4-DRI clears damaged cells, GHK-Cu supports tissue remodeling, collagen synthesis, and wound healing. GHK-Cu influences over 4,000 genes related to tissue repair. This combination addresses the concern that clearing senescent cells creates a temporary deficit that regenerative peptides can help fill.

Week 1–2: FOXO4-DRI 2–3 mg EOD (senolytic phase)
Week 3: Rest (clearance and recovery)
Week 4–7: GHK-Cu 1–2 mg/day (tissue rebuilding)

FOXO4-DRI + MOTS-c — Senolytic-Metabolic Sequence

MOTS-c is a mitochondrial-derived peptide that supports metabolic function and cellular energy production. Sequencing it after FOXO4-DRI helps restore mitochondrial tone in the regenerating tissue. This reflects the phased protocol where metabolic support follows senescent cell clearance.

Week 1–2: FOXO4-DRI 2–3 mg EOD (senolytic phase)
Week 3–4: Rest (clearance and recovery)
Week 5–8: MOTS-c 5–10 mg 3x/week (metabolic support)

Sequence, do not stack simultaneously. The clean window principle is central to FOXO4-DRI protocols. Pause all regenerative peptides for at least 1 week before and after your senolytic course. The phased approach mirrors natural tissue repair: clearance first, then stabilization, then regeneration.

FOXO4-DRI Safety & Side Effects

All safety data comes from mouse studies and community self-reports. No human clinical safety study has been conducted. The mouse studies consistently describe FOXO4-DRI as “well tolerated” with no reported adverse effects on healthy cells, but mouse tolerability does not guarantee human safety.

Commonly Reported Side Effects

Flu-like symptoms — the most frequently reported effect, typically appearing within 24–48 hours of injection. Described as a mild feeling of coming down with something. Users interpret this as the immune response to dying senescent cells releasing their contents.
Fatigue and energy fluctuations — the second most common report. Some users experience transient energy dips, particularly in the first few days of a cycle. Energy typically normalizes within a few days of completing the course.
Injection site soreness — can persist for several days, notably longer than with most other peptides. Some users report soreness lasting nearly a week at higher doses (2.5+ mg per injection).

Less Common Reports

Headaches or migraines (reported at higher doses, 5+ mg/day)
Transient sleep disruption
Temporary mood changes
Increased bowel movements

Theoretical and Preclinical Concerns

p53 pathway interference — FOXO4-DRI acts on p53, one of the body’s most critical tumor suppressor proteins. The peptide’s selectivity for senescent cells (where FOXO4 is upregulated) mitigates this concern, but long-term effects of repeated p53 pathway modulation are unknown. No studies have reported increased cancer incidence following treatment.
Removal of beneficial senescent cells — some senescent cells serve protective roles in wound healing, tissue repair, and potentially in isolating latent micro-cancers. FOXO4-DRI is a general senolytic that does not distinguish between harmful and beneficial senescent cells. The original researchers moved on to developing targeted senolytics for this reason.
Pulmonary hypertension risk — Born et al. (Circulation, 2023) showed that eliminating senescent cells worsened pulmonary hypertension in mice and rats. Individuals with known pulmonary conditions should avoid FOXO4-DRI.
Structural tissue integrity — senescent cells contribute to structural integrity in some tissues, including blood vessels. Clearing them could theoretically compromise tissue stability, though no published study has confirmed this in the context of FOXO4-DRI.

Contraindications: Active cancer or recent cancer history (p53 pathway involvement). Known pulmonary hypertension or significant pulmonary disease. Active tissue repair (post-surgery, wounds, heavy training). Pregnancy or breastfeeding. Active infection or acute physiological stress. Individuals under 18. Anyone taking immunosuppressive medications should consult their physician.

Selectivity Ratio

Dr. Peter de Keizer, the lead researcher, publicly estimated FOXO4-DRI's selectivity at approximately 10:1, meaning for every 10 senescent cells eliminated, approximately 1 healthy cell may also be affected. He has stated he believes this ratio could be improved to 100:1 with next-generation compounds, which is what his company Cleara Biotech is developing (CL04177/CL04183).

Regulatory status: FOXO4-DRI is not FDA-approved for human use. It is classified as a research chemical sold for research purposes only. It is not a controlled substance in most jurisdictions and is not listed by WADA. Regulations vary by country. Always verify your local laws before purchasing.

Common Mistakes

Skipping the clean window before and after treatment: FOXO4-DRI triggers programmed cell death in senescent cells. Running regenerative or growth-promoting peptides (MOTS-c, GHK-Cu, CJC-1295, Ipamorelin) concurrently sends conflicting biological signals. Pause all restorative peptides for at least one week before starting and one week after finishing your FOXO4-DRI course. Let the clearance phase complete before beginning tissue rebuilding.

Expecting dramatic visible results from a single course: FOXO4-DRI works at the cellular level by removing senescent cells. Younger, healthier individuals may not have enough senescent cell burden to notice subjective changes. Community reports show that users with pre-existing chronic conditions are more likely to report benefits. Roughly 25% of users report no noticeable effect. Evaluate over multiple cycles and consider objective biomarkers (epigenetic testing, inflammatory markers) rather than relying solely on how you feel.

Using doses far above what the community has tested: With zero human clinical trials, there is no established safe dose ceiling. The mouse-equivalent human dose (approximately 28 mg) has not been tested in controlled human settings. Community experience is concentrated at 1–8 mg per dose. Exceeding this range without medical supervision carries unknown risk. Start at the low end of community protocols and titrate based on tolerance.

Running FOXO4-DRI during active tissue repair: Senescent cells play a role in wound healing, tissue remodeling, and post-surgical recovery. Running a senolytic during active tissue repair could impair these processes. Avoid FOXO4-DRI during recovery from surgery, injury, heavy training cycles, or active infections. Wait until you are in a stable physiological state.

Assuming cheap sources contain real FOXO4-DRI: FOXO4-DRI is a 43-amino-acid peptide made entirely from D-amino acids (mirror-image amino acids), which makes it significantly more expensive to synthesize than standard L-amino acid peptides. Reputable sources typically charge $200 or more per 10 mg vial. Unusually cheap products are likely degraded, impure, or not the actual compound. Certificates of analysis for this peptide are rare, and third-party testing is the only way to verify authenticity.

Treating FOXO4-DRI like a daily maintenance peptide: FOXO4-DRI is a senolytic, not a daily supplement. It is designed to be used in short, intensive courses (typically 3–20 days) repeated 1–3 times per year. The mechanism is to trigger a clearance event, then let the body recover and regenerate. Continuous daily use is not supported by any research protocol and unnecessarily increases exposure to a compound with no human safety data.

Frequently Asked Questions

Next Steps

Calculate Your Dose

Use our free calculator to get exact syringe volumes for your vial size and target dose.

Open Calculator

Epitalon Dosage Guide

Complementary longevity peptide. Telomerase activation protocols for sequencing after FOXO4-DRI.

View Guide

Browse All Dosage Guides

Evidence-based dosing protocols for 50+ research peptides.

Browse Guides